Psychedelics therapy provider Optimind Pharma Corp. entered into an acquisition agreement with Wolf Acquisitions 1.0 Corp., an arm's length private British Columbia corporation with investments in the psychedelics industry and one of its wholly-owned subsidiaries.
Optimind looks to accelerate the adoption of the MindSetting TRIP Protocol for ketamine-assisted therapy and other psychedelic enhanced psychotherapy modalities.
Toronto, Ontario (Newsfile Corp. - September